Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

NCT03072043 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndrome
Acute Myeloid Leukemia
Myeloproliferative Neoplasm
Chronic Myelomonocytic Leukemia

Interventions

DRUG: APR-246
DRUG: Azacitidine

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]